[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565054":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":40,"collaborators":42,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":26,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":72,"overallStatus":77,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":26},{"fullName":5,"class":6},"Ginefiv","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PPOS - study group","EXPERIMENTAL","Patients belonging to this arm will initiate controlled ovarian stimulation by administering FSHr gonadotropin at doses between 225 IU-300 IU\u002Fday (according to patient characteristics) + 10mg medroxyprogesterone\u002Fday (IMP) from day 2-3 of their menstrual cycle.\n\nBoth groups will continue with the usual regimen of administration of all medications related to Ovarian Stimulation",[13],"Drug: Medroxyprogesterone Acetate 10 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"GnRH antagonists - control group","ACTIVE_COMPARATOR","Patients belonging to this arm will initiate controlled ovarian stimulation by administering FSHr gonadotropin at doses between 225 IU-300 IU\u002Fday (according to patient characteristics) from day 2-3 of their menstrual cycle, and treatment with the GnRH antagonist at a dose of 0.25 mg\u002Fday from the 6th day of stimulation or when a follicle with a size equal to or greater than 14mm is present. Both groups will continue with the usual regimen of administration of all medications related to Ovarian Stimulation",[19],"Drug: Ganirelix",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ganirelix","Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Medroxyprogesterone Acetate 10 MG","Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.",[9],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Claudia Blancafort González-Casabón, MD","CONTACT","+34647437121","c.blancafort@ginefiv.com",{"name":38,"role":34,"phone":26,"phoneExt":26,"email":39},"Joaquín Llácer, phD","j.llacer@gmail.com",{"type":41,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[43],{"name":44,"class":45},"Theramex","INDUSTRY","100565054","phase-4-protocol-with-progestin-primed-ovarian-stimulation-ppos-from-the-beginning-of-stimulation-versus-protocol-with-gnrh-antagonists-for-ovarian-stimulation-in-patients-undergoing-duostim-with-embryo-accumulation-for-pgt-a-100565054",false,"NCT06637189","Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.","PPDUO","Inclusion Criteria:\n\n* Regular menstrual cycles between 21 and 35 days, inclusive.\n* Indication of IVF with PGT-A.\n* Both ovaries present.\n* Ability to participate and complete the study.\n* Give and sign the consent to participate in the study.\n\nExclusion Criteria:\n\n* Endometriosis grade III\u002FIV\n* Concurrent participation in another study",true,"FEMALE","18 Years","43 Years",{"count":58,"type":59},144,"ESTIMATED","INTERVENTIONAL",[62],"PHASE4","The PPOS protocol (Progestin-primed Ovarian Stimulation) involves avoiding ovulation during ovarian stimulation with progesterone. It is a reliable and safe protocol that has been widely used in recent years for in vitro fertilization, as it reduces the number of injections needed during controlled ovarian stimulation and is more cost-effective for patients.\n\nThe aim of this study is to compare two methods of ovarian stimulation for in vitro fertilization: the PPOS protocol (Group A) and the conventional protocol with injected antagonists (Group B). The goal is to determine whether both methods are equally effective in obtaining euploid embryos in the context of double ovarian stimulation.",[65,66,67,68,69,70,71],"Stimulation in the Ovary","Embryo","Oocyte","Oocyte Retrieval","Fertilization in Vitro","Blastocyst","PGT-A",[73,74,75,76,71],"duostim","ovarian stimulation","progesterone","GnRH antagonists","NOT_YET_RECRUITING","2024-10-10",{"date":80,"type":81},"2024-10-15","ACTUAL",{"date":80,"type":59},{"date":84,"type":59},"2025-12-31",{"name":5,"class":6}]